Section Arrow
Quote
DMRA.NASDAQ
- Damora Therapeutics, Inc.
Quotes are at least 15-min delayed:2026/08/01 17:02 EDT
Regular Hours
Last
 28.99
-0.22 (-0.75%)
Day High 
30.27 
Prev. Close
29.21 
1-M High
34.89 
Volume 
314.51K 
Bid
11.8
Ask
42.89
Day Low
28.65 
Open
29.21 
1-M Low
25.76 
Market Cap 
1.80B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 30.18 
20-SMA 29.93 
50-SMA 25.86 
52-W High 38.3251 
52-W Low 2.45 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.68/-1.96
Enterprise Value
1.80B
Balance Sheet
Book Value Per Share
6.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.